Lyme Disease Plasma

Lyme Disease Plasma for Infectious Disease and Host Response Research

Lyme Disease Plasma is collected from IRB-consented donors diagnosed with Lyme disease and processed under standardised SOPs. Lyme disease is an infectious disease caused by Borrelia burgdorferi sensu lato, transmitted by Ixodes ticks, and the clinical picture reflects the host immune response to that infection and to its dissemination. These samples support research into the host response, biomarker discovery and therapeutic development, including persistent symptoms after treatment.

What Lyme Disease Plasma Reveals

• Lyme disease progresses through recognised stages: early localised infection with erythema migrans, early disseminated disease with manifestations such as multiple skin lesions, cranial neuropathy or carditis, and late disease presenting most often as Lyme arthritis or neuroborreliosis. Plasma from stage-annotated donors is what allows host-response markers to be mapped onto that progression.
• Standard diagnosis relies on two-tier antibody testing, which is insensitive in the first weeks of infection because seroconversion has not yet occurred. That diagnostic gap is the main reason disease-state plasma is valuable: direct-detection and host-response approaches are being developed specifically to fill it.
• B. burgdorferi is present in blood at very low abundance and localises to tissue, so pathogen nucleic acid detection in plasma is technically demanding. Work in this area depends on well-characterised patient plasma rather than spiked controls.
• Antibody responses persist for months to years after successful antibiotic treatment, so serology cannot establish cure. Plasma-based cytokine, chemokine, proteomic and metabolomic signatures are therefore being investigated as treatment-response and resolution markers.
• A subset of patients report persistent symptoms after standard antibiotic therapy. The mechanism remains unresolved, and longitudinally characterised plasma from these donors is central to work on immune activation signatures in that population.
• Tick-borne co-infections including Anaplasma phagocytophilum and Babesia microti share the same vector and can confound host-response interpretation, so co-infection status is a meaningful stratification variable rather than an afterthought.

Donor Stratification Available

• Disease stage: early localised with erythema migrans, early disseminated, or late Lyme disease
• Objective manifestations where documented: Lyme arthritis, neuroborreliosis, carditis, or cutaneous only
• Serostatus by two-tier testing where documented, including IgM and IgG immunoblot results
• Treatment status and timing: pre-treatment, on antibiotics, or post-treatment with interval since completion
• Persistent symptoms after treatment versus symptom resolution
• Geographic region of exposure and documented tick-borne co-infection status; matched healthy controls available

Product Features

• Plasma isolated from clinically confirmed Lyme disease donors
• Research Use Only (RUO)
• Rigorous donor screening and sample quality checks
• Anticoagulant selection available on request
• Standard and custom volumes; volumes reported per lot
• Matched serum, whole blood and PBMC from the same donors available on request

De-identified Donor Data

• Age, sex, race, medication, diagnosis method, disease severity and stage
• Optional: comorbidities, lab values, and clinical history
• Treatment history and symptom duration available on request

Applications

• Cytokine and chemokine profiling of the host response to Borrelia infection
• Plasma proteomic and metabolomic signature discovery for early diagnosis
• Direct-detection assay development, including low-abundance nucleic acid and antigen approaches
• Serology and immunoassay development, including matched-matrix comparability work
• Treatment-response and resolution biomarker research
• Persistent post-treatment symptom research and immune activation profiling
• Tick-borne co-infection differential marker studies
• Disease-state control matrix for infectious disease immunoassay qualification

Other Lyme Disease Specimen Types

• Lyme Disease Serum
• Lyme Disease Whole Blood
• Lyme Disease PBMC
• Lyme Disease Leukopak
• Lyme Disease Bulk Plasma

Quality and Compliance

• IRB-approved protocols
• Informed donor consent
• Standardized collection and processing SOPs
• HIPAA-compliant donor data protection

Ordering & Customization

Lyme disease plasma is available in both standard and custom volumes to meet your research needs. For pricing, current availability, or a quote on a stratified donor cohort, contact learnmore@sanguinebio.com.

International Orders: For international shipments or country-specific documentation requirements, please contact us at learnmore@sanguinebio.com to ensure compliance with your local regulations. To browse other disease states in this specimen type, visit our human plasma page.